Selected Publications

Cevasco C, Ivanciu L, Gansner JM, Camire RM, Lundberg Slingsby MH.: Hepatic plasminogen lowering with a galnac-conjugated siRNA reduces plasmin generation and fibrinolysis but has no effect on thrombin generation in rats and mice. 67th American Society of Hematology Annual Meeting, Orlando, FL, Poster presentation Dec 2025.

Leyes Porello SE, Chau JQ, Lee K, Johnsen J, Lund J, a\Ivanciu L, Sameslo-Jones BJ.: Mim8 improves the in vivo hemostasis of select hemophilia B causing factor IX variants. 67th American Society of Hematology Annual Meeting, Orlando, FL, Poster presentation Dec 2025.

Chau JQ, Leyes Porello SE, Ivanciu L, and Samelson-Jones BJ: Comparison of hemostatic dosing of factor IX and Padua (R338L) in multiple hemophilia B mouse models. 67th American Society of Hematology Annual Meeting, Orlando, FL, Poster presentation Dec 2025.

Krohn L, Ivanciu L, Cevasco C, Deaton AM, Ward LD, Gansner JM, Camire RM, and Lundberg Slingsby MH.: Lowering plasminogen is not associated with risk of thrombosis: Evidence from human proteomics, Mendelian Randomization, and mouse injury models. American Society of Human Genetics (ASHG), Boston, MA, Poster presentation October 2025.

Ivanciu L, Krohn L, Cevasco C, Deaton AM, Ward LD, LoGerfo PJ, Gansner JM, Camire RM, Slingsby MHL.: Hepatic plasminogen lowering with RNA interference for the treatment of bleeding disorders is unlikely to pose thrombotic risk based on UK Biobank analysis and mouse models of provoked thrombosis. European Hematology Association (EHA) Congress, Milan, Italy, Oral presentation Jun 2025.

Ivanciu L and Camire RM: Blood Coagulation Factor IX: structure, function and regulation. IUBMB Life; "From DNA to protein: molecular mechanisms and tailored approaches to correct genetic defects associated with human disorders" doi: https://doi.org/10.1002/iub.70024 (eds.). 2025 Notes: co-corresponding author.

Poncz M, Zaitsev S, Ahn H, Kowalska MA, Bdeir K, Vladimirovich K, Ivanciu L, Camire RM, Cines DB, Stepanova V.: Packaging of supplemental urokinase into alpha-granules of the in vitro-grown megakaryocytic for targeted nascent clot lysis. Blood Advances 8(14): 3798-3809, Jul 2024.

Ivanciu L, Bos MHA, Camire RM: Enhanced activation of FVIII positively impacts clot formation in vivo using hemophilia A mice. Thrombosis & Hemostasis Summit of North America, Chicago, IL, Oral presentation Apr 2024.

Quin SM, Ivanciu L, Aymobil F, and Camire RM: A monoclonal antibody targeting human FV enhances thrombin generation and reduces bleeding in hemophilia A mouse model Annual Bleeding Disorders Conference, National Harbor, MD, Poster presentation Aug 2023.

Ivanciu L: Optimization of a tail vein transection bleeding model in hemophilia A. Journal of Thrombosis and Haemostasis 21(5): 1107-1108, May 2023.